Canada Life’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Canada Life’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-4,651	Closed	-$28K	–	2604
2019 Q2	$28K	Hold	4,651	–	–	﹤0.01%	2553
2019 Q1	$62K	Hold	4,651	–	–	﹤0.01%	2209
2018 Q4	$42K	Hold	4,651	–	–	﹤0.01%	2436
2018 Q3	$65K	Hold	4,651	–	–	﹤0.01%	2330
2018 Q2	$73K	Hold	4,651	–	–	﹤0.01%	2306
2018 Q1	$80K	Hold	4,651	–	–	﹤0.01%	2235
2017 Q4	$102K	Buy	4,651 +2,305	+98%	+$74.1K	﹤0.01%	2168
2017 Q3	$91K	Hold	2,346	–	–	﹤0.01%	2180
2017 Q2	$71K	Hold	2,346	–	–	﹤0.01%	2213
2017 Q1	$85K	Hold	2,346	–	–	﹤0.01%	2163
2016 Q4	$118K	Hold	2,346	–	–	﹤0.01%	2071
2016 Q3	$123K	Hold	2,346	–	–	﹤0.01%	2066
2016 Q2	$97K	Hold	2,346	–	–	﹤0.01%	2112
2016 Q1	$95K	Hold	2,346	–	–	﹤0.01%	1830
2015 Q4	$97K	Buy	+2,346	New	+$78.6K	﹤0.01%	1788

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Life's FPRX Position: Q3 2019 in Review

Canada Life sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2019, closing a stake of 4,651 shares — an estimated $28K sold.

Canada Life first reported a position in FPRX in Q4 2015 and held it in 15 quarters. The position peaked at $123K in Q3 2016. 103 funds tracked by Wall St. Rank hold FPRX as of Q3 2019.

Canada Life reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Canada Life sold 4,651 Five Prime Therapeutics, Inc. shares in Q3 2019, an estimated $28K.
Canada Life first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 15 quarters.
Canada Life's Five Prime Therapeutics, Inc. position peaked at $123K in Q3 2016.
103 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2019.

Based on Canada Life's 13F filing for Q3 2019, filed 25 Oct 2019.